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Electrical storm refers to a situation when rapid
clustering of episodes of malignant ventricular tachy-
arrhythmias (VT) develops requiring repetitive at-
tempts at cardioversion. This situation is seen in
patients with acute coronary syndrome (ACS) as
well as in some patients with the implantable car-
dioverter-defibrillator (ICD). A similar situation is
encounterd in victims of out-of-hospital cardiac ar-
rest in whom VT is the mechanism of out-of-hospi-
tal cardiac arrest. In this group of patients, besides
management of hypoxia, electrolyte disturbances,
acidosis, volume depletion, etc., drugs are admin-
istered to either assist direct current (DC) cardio-
version and/or maintain a stable rhythm. The first
line recommended anti-arrhythmic therapy these
days is intravenous (IV) amiodarone and not lido-
caine [1]. This change came around gradually in the
last several years when head-to-head comparison
of IV amiodarone and lidocaine showed the first
drug to be unequivocally superior [2]. In fact lido-
caine prophylaxis in ACS appears to be associated
with increased mortality and this practice has large-
ly been abandoned [3]. However, lidocaine is still
being used by some for out-of-hospital cardiac ar-
rest as a second tier drug. Other second-tier drug
therapy in this situation also includes intravenous
magnesium and procainamide.
Although IV amiodarone is available worldwide,
its use is disallowed in Japan. However, luckily for
the Japanese, one of their drug companies has
introduced a new selective Ikr blocker [4] that has
been in use since June 2000 in situations when
IV amiodarone would be indicated, i.e., primarily in
patients with electrical storm and out-of-hospital
cardiac arrest [5–7]. Although the drug, Nifekalant,
is a pure Ikr blocker and as such is reverse-use
dependent specially in the presence of fast VT, yet
it has proven effective. An efficacy rate approach-
ing 75% has been reported both in patients with
electrical storm and in out-of-hospital cardiac arrest.
However, the drug as in the case of other pure Ikr
blockers can result in significant QT prolongation
and induce torsade de pointe VT. In other words,
the drug can successfully terminate, for instance,
VT in the setting of ACS and then induce a torsade
de pointe type VT [7]. In this issue of Cardiology
Journal, Dr. Amino and associates from Japan re-
ported on the efficacy of the combination of Nifeka-
lant with acute left stellate ganglion blockade (LSGB)
in patients with intractable VT in out-of-hospital car-
diac arrest [8]. As expected DC cardioversion and
Nifekalant were effective in 40 of 55 patients (73%).
In the remaining 15 patients, VT continued in spite of
repeated doses of Nifekalant. In this group, acute
LSGB was performed in 11 patients and resulted in
a stable sinus rhythm in 7 (64%). The short-term mor-
tality was 45% in the LSGB group and 100% in the
4 patients who comprised the non-LSGB group. The
numbers are relatively small and the results are hardly
impressive if we remember that only 2 patients out
of the LSGB group seem to have survived long term.
Never the less, the study is of interest because it
re-focuses attention on a rarely utilized management
modality in a very serious clinical situation.
The rationale for the use of acute LSGB as
means of sympathetic blockade in the setup of elec-
trical storm or out-of-hospital cardiac arrest is
straight forward. A majority, if not all, of these pa-
tients will have an increased sympathetic drive. The
latter, is universally accepted as arrhythmogenic
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especially in patients with ACS, patients with
ischemic and non-ischemic cardiomyopathy, and
patients with certain channelopathies. The exact
electrophysiological mechanism(s) by which in-
creased sympathetic drive to the heart can be ar-
rhythmogenic in most of the above situations is not
fully understood. However, innumerable experi-
mental [9, 10] and clinical [11, 12] data have shown
that blocking the increased sympathetic drive to the
heart in both its acute and chronic versions can be
significantly antiarrhythmic. Sympathetic blockade
could be achieved by intravenous beta-blocking
drugs like propanolol or esmolol or by acute LSGB.
The authors argue in favor of LSGB by citing its
specific blockade of sympathetic innervations to the
left ventricle and the potentially negative inotropic
and chronotropic effects of IV beta-blockade in these
settings. Even though LSGB has an alpha-blocking
effect in addition to beta-blocking effect, several
studies have demonstrated that LSGB and beta-
blockade are equally effective in treating post-myo-
cardial infarction malignant VT [11, 13]. Few patients
receiving beta-blocking agents for electrical storm
can develop electromechanical dissociation [13].
However, a strong counter argument in favor of IV
beta-blockade is its ease of use and ready availabil-
ity compared to acute LSGB. The latter requires
some degree of expertise, is not always success-
ful, and is more difficult to implement when time is
of the essence. Further, the effects of acute LSGB
can dissipate resulting in recurrence of malignant
VT [13]. The present report did not comment on
this event and the strategy put in place to rectify
the situation. In fact it may turn out that the best use
of acute LSGB would be in hospitalized patients with
electrical storm who are relatively more stable com-
pared to out-of-hospital cardiac arrest patients.
Acute LSGB is just one attempt to address the
challenge of current management of electrical storm
and out-of-hospital cardiac arrest. Another manage-
ment modality has been rescue VT ablation of drug
refractory electrical storm in patients with acute
coronary syndrome [14], with ischemic cardiomy-
opathy [15], or ICD [16].
The dramatic change in the last decade in the
management of malignant VT is explained both by
the development of effective nonpharmacologic
therapies such as targeted ablation of the arrhyth-
mogenic tissue and the ICD as well as the limited
efficacy and proarrhythmic potential of current an-
tiarrhythmic agents. The failure of development of
a new antiarrhythmic drug particularly for electri-
cal storm in the setting of acute coronary syndrome
is not because of lack of trying on the part of the
pharmaceutical industry. In fact different innovative
approaches to antiarrhythmic drug therapy have
been exploited [17]. To mention a few: 1) The ade-
nosine-triphosphate sensitive (KATP) K+ channel is
a metabolic sensor that opens during myocardial
ischemia [18] and has a key role in ischemic action
potential duration shortening. KATP has a complex
role, mediating cardiac protective as well as ar-
rhythmogenic functions. These actions can be dis-
sociated with cardioprotective function mediated
largely by a mitochondrial KATP channel and elec-
trical changes due to a sarcolemmal channel [19].
Certain compounds can selectively block the sar-
colemmal KATP channels and prevent associated
malignant VT [20]; 2) Cell-to-cell communications
and their pharmacological manipulation has yielded
new approaches to ischemia-associated uncoupling
of gap junctions and its role in promoting malignant
VT [21]. Several recent experimental studies have
shown that drugs that enhance gap junction conduct-
ance like rotigaptide can be antiarrhythmic in the
setting of acute ischemia [22]; 3) The identification
of calstabin2 depleted ryanodine receptor (RyR2) as
a source of diastolic sarcoplasmic reticulum (SR) Ca2+
leak in catcholaminergic polymorphic ventricular
tachycardia and in patients with heart failure sus-
ceptible to malignant VT has led to the hypothesis
that increasing calstabin2 binding to RyR2 could be
a potential new target to treat triggered malignant
VT [23]. Whether this approach is helpful in arrhyth-
mias secondary to acute ischemia is not known.
There are at least 3 reasons why no new effec-
tive antiarrhythmic drug against ischemia-related
malignant VT has made it to the clinical setting in
the past several years: 1) The heterogeneity of the
arrhythmogenic substrate during ischemia and in
the post-infarction period is a daunting obstacle;
2) There is a plethora of experimental studies show-
ing significant antiarrhythmic effect of one or an-
other new drug but preciously little clinical data. It
is indeed reasonable to question the validity of some
of the experimental models currently in use for new
antiarrhythmic drug development; 3) In view of this
author, a main limitation for the development of
a new clinically effective antiarrhythmic drug ther-
apy for ischemia-related VT is simply our current
incomplete understanding of the underlying elec-
trophysiological mechanisms. One prominent ex-
ample is the recent report showing that ischemia/
/reperfusion associated ventricular arrhythmias
may be secondary to fast oscillatory intracellular
Ca2+ responses that can trigger local ventricular de-
polarizations [24]. The latter, based on how these
conduct to the surrounding myocardium can explain
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both the sporadic ventricular premature beat as well
as ventricular fibrillation.
In summary, the report of Amino and associ-
ates is important for focusing the attention on the
challenge in management of electrical storm and
out-of-hospital cardiac arrest and the need for con-
tinued search for new management modalities in
these situations.
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